Market Research Logo

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026

Summary


Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized PCa can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’sProvenge (sipuleucel-T), Sanofi’s Jevtana (cabazitaxel), Johnson & Johnson’s (J&J’s) Zytiga (abiraterone acetate), Astellas/Pfizer’s Xtandi (enzalutamide), and Bayer’s Xofigo (radium 223 dichloride).

It is estimated that the value of the prostate cancer (PCa) market in 2016 was about $7.7B across the 7MM. This market is defined as sales of major branded drugs commonly prescribed for PCa patients across the 7MM, excluding bone therapies. Over half of these sales, or about $4.5B (59%), were generated in the US, with the 5EU representing the next largest region by sales, estimated to be at around $2.1B (over 27%). Japan contributed the smallest proportion of sales to the global PCa market, with 2016 sales of just over $1B (about 13.9%).

By 2026, itis projected that the PCa sales will rise to about $13.7B in the 7MM, at a Compound Annual Growth Rate (CAGR) of about 6%.

Major drivers of the growth of the PCa market over the forecast period include -

  • A rapidly aging population, resulting in PCa incident case increases in the markets covered in this report. Overall, across the 7MM, the diagnosed incidence of PCa is expected to increase by an Annual Growth Rate (AGR) of 1.7% from 2016−2026.
  • The anticipated label extensions of Johnson & Johnson (J&J)’s Zytiga and Astellas/Pfizer’s Xtandi into hormone-sensitivePCa (HSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Xtandi has become an established presence in the PCa treatment algorithm, and its extended use in multiple PCa patient segments, and its continued patent protection, ensures that it will be the market-leading PCa drug by the end of the forecast period in 2026.
  • The launch of nine new premium-priced therapies for the treatment of PCa by 2026. GlobalData expects the launch of eight pipeline agents for castration-resistant prostate cancer (CRPC), and one for the treatment of localized PCa. In addition, weexpects label extensions for all second-generation hormonal agents in the treatment of HSPC.
The report PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026 , provides the key metrics for prostate cancer in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report during the forecast period from 2016 to 2026.

In particular, this report provides the following -
  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: AB Science, AbbVie, Advantagene, Amgen, Aptevo Therapeutics, Asana BioSciences

Scope
  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Prostate Cancer: Executive Summary
2.1 Value of Prostate Cancer Market to Increase Two-Fold By 2026
2.2 Xtandi to Become the Undisputed Leader in the Global Prostate Cancer Market
2.3 Prostate Cancer Treatment Landscape to Undergo Dramatic Change
2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine
2.5 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
2.6 What Do the Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Prostate Cancer (2016-2026)
5.5.1 Diagnosed Incident Cases of Prostate Cancer
5.5.2 Age-Specific Incident Cases of Prostate Cancer
5.5.3 Incident Cases by Stage at Diagnosis
5.5.4 Incident Cases by Risk of Biochemical Recurrence
5.5.5 10-Year Diagnosed Prevalent Cases of Prostate Cancer
5.5.6 10-Year Prevalent CRPC Cases
5.5.7 10-Year Prevalent Metastatic Prostate Cancer Cases
5.5.8 10-Year Prevalent mCRPC Cases with HRD Mutations
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.3.1 Diagnosis
6.3.2 Clinical Practice
6.4 France
6.4.1 Diagnosis
6.4.2 Clinical Practice
6.5 Germany
6.5.1 Diagnosis
6.5.2 Clinical Practice
6.6 Italy
6.6.1 Diagnosis
6.6.2 Clinical Practice
6.7 Spain
6.7.1 Diagnosis
6.7.2 Clinical Practice
6.8 UK
6.8.1 Screening and Diagnosis
6.8.2 Clinical Practice
6.9 Japan
6.9.1 Diagnosis
6.9.2 Clinical Practice
7 Competitive Assessment
7.1 Overview
7.2 Second-Generation Hormonal Therapies
7.2.1 Zytiga (Abiraterone Acetate)
7.2.2 Xtandi (Enzalutamide)
7.3 Targeted Therapies
7.3.1 Xofigo (Radium 223 Dichloride)
7.4 Chemotherapies
7.4.1 Jevtana (Cabazitaxel)
7.5 Therapeutic Vaccines
7.5.1 Provenge (Sipuleucel-T)
7.6 First-Generation Hormonal Therapies
7.6.1 Zoladex (Goserelin Acetate)
7.6.2 Lupron Depot (Leuprolide Acetate)
7.6.3 Eligard (Leuprolide Acetate)
7.6.4 Trelstar (Triptorelin Pamoate)
7.6.5 Vantas (Histrelin Acetate)
7.6.6 Firmagon (Degarelix)
7.6.7 Casodex (Bicalutamide)
7.7 Bone Therapies
7.7.1 Zometa (Zoledronic Acid)
7.7.2 Xgeva (Denosumab)
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Therapeutic Options for Non-Metastatic CRPC
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance and Agents Able to Overcome Resistanceto Available Therapies
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Identification of New Targets and Positive Predictive Biomarkers of Response
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Immunotherapies
9.3.1 ProstAtak (Aglatimagene Besadenovec)
9.3.2 Stapuldencel-t (DCVAC/PCa)
9.3.3 ITK-1
9.3.4 Tecentriq (Atezolizumab)
9.4 Second-Generation Hormonal Therapies
9.4.1 Apalutamide (ARN-509)
9.4.2 Darolutamide (ODM-201)
9.5 Targeted Therapies
9.5.1 Masitinib (AB1010)
9.5.2 Lynparza (Olaparib)
9.5.3 Rubraca (Rucaparib Camsylate)
9.5.4 Ipatasertib (GDC-0068)
9.6 First-Generation Hormonal Therapies
9.6.1 Relugolix (TAK-385)
9.7 Promising Drugs in Early-Stage Development
9.7.1 Targeting the P13K/AKT/mTOR Pathway
9.7.2 Immunotherapies
9.7.3 Prostate-Specific Membrane Antigen-Targeted Therapies
9.7.4 Hormonal Therapies
9.8 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Astellas
10.3.2 AstraZeneca
10.3.3 Bayer
10.3.4 Clovis Oncology
10.3.5 Johnson & Johnson
10.3.6 Pfizer
10.3.7 Roche
10.3.8 Sanofi
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Prostate Cancer Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.4 Primary Research - KOLs Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Epidemiology Reviewers
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: Prostate Cancer: Key Metrics in Seven Major Pharmaceutical Markets
Table 2: Stage Definitions for PCa
Table 3: NCCN Risk-Category Classification System for PCa
Table 4: Risk Factors and Comorbidities for Prostate Cancer
Table 5: AJCC Staging of Prostate Cancer
Table 6: Risk Category Definitions
Table 7: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026
Table 8: 7MM, 10-Year Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026
Table 9: Treatment Guidelines for Prostate Cancer
Table 10: Most-Prescribed Drugs for Prostate Cancer by Drug Class in the Global Markets in 2016
Table 11: Country Profile - US
Table 12: Country Profile - France
Table 13: Country Profile - Germany
Table 14: Country Profile - Italy
Table 15: Country Profile - Spain
Table 16: Country Profile - UK
Table 17: Country Profile - Japan
Table 18: Leading Branded Treatment for PCa, 2017
Table 19: Product Profile - Zytiga
Table 20: Efficacy of Zytiga in Chemotherapy-Naïve mCRPC
Table 21: Efficacy of Zytiga in Chemotherapy-Resistant mCRPC
Table 22: Results of the LATITUDE Trial of Zytiga
Table 23: Zytiga SWOT Analysis, 2017
Table 24: Product Profile - Xtandi
Table 25: Efficacy of Xtandi in Chemotherapy-Naïve mCRPC
Table 26: Efficacy of Xtandi in Chemotherapy-Resistant mCRPC
Table 27: Xtandi SWOT Analysis, 2017
Table 28: Product Profile - Xofigo
Table 29: Efficacy of Xofigo in mCRPC
Table 30: Xofigo SWOT Analysis, 2017
Table 31: Product Profile - Jevtana
Table 32: Efficacy of Jevtana as Second-Line Treatment Post-Docetaxel Failure in mCRPC
Table 33: Jevtana SWOT Analysis, 2017
Table 34: Product Profile - Provenge
Table 35:Efficacy of Provenge in mCRPC
Table 36: Provenge SWOT Analysis, 2017
Table 37: Product Profile - Zoladex
Table 38:Efficacy of Zoladex in mCRPC
Table 39:Efficacy of Zoladex as Neoadjuvant/Adjuvant Treatment
Table 40: Zoladex SWOT Analysis, 2017
Table 41: Product Profile - Lupron Depot
Table 42: Lupron Depot SWOT Analysis, 2017
Table 43: Product Profile - Eligard
Table 44:Efficacy of Eligard in Advanced PCa
Table 45: Eligard SWOT Analysis, 2017
Table 46: Product Profile - Trelstar
Table 47:Efficacy of Trelstar in Advanced PCa
Table 48: Trelstar SWOT Analysis, 2017
Table 49: Product Profile - Vantas
Table 50: Vantas SWOT Analysis, 2017
Table 51: Product Profile - Firmagon
Table 52:Efficacy of Firmagon in Advanced PCa
Table 53: Firmagon SWOT Analysis, 2017
Table 54: Product Profile - Casodex
Table 55: Casodex SWOT Analysis, 2017
Table 56: Product Profile - Zometa
Table 57:Efficacy of Zometa in Advanced PCa
Table 58: Zometa SWOT Analysis, 2017
Table 59: Product Profile - Xgeva
Table 60:Efficacy of Xgeva in Advanced mCRPC
Table 61: Xgeva SWOT Analysis, 2017
Table 62: Product Profile - ProstAtak
Table 63:Efficacy of ProstAtak as Adjuvant Treatment in Combination with Radiotherapy in Localized PCa
Table 64: ProstAtak SWOT Analysis, 2017
Table 65: Product Profile - Stapuldencel-t
Table 66:Efficacy of Stapuldencel-t in mCRPC
Table 67:Results from the Randomized Phase II Study of Stapuldencel-t in mCRPC
Table 68: Stapuldencel-t SWOT Analysis, 2017
Table 69: Product Profile - ITK-1
Table 70:Efficacy Results from the Phase II Study of ITK-1 in mCRPC
Table 71: ITK-1 SWOT Analysis, 2017
Table 72: Product Profile - Tecentriq
Table 73: Tecentriq SWOT Analysis, 2017
Table 74: Product Profile - Apalutamide
Table 75:Efficacy of Apalutamide in nmCRPC
Table 76:Efficacy of Apalutamide in mCRPC
Table 77: Apalutamide SWOT Analysis, 2017
Table 78: Product Profile - Darolutamide
Table 79:Efficacy of Darolutamide in nmCRPC
Table 80: Darolutamide SWOT Analysis, 2017
Table 81: Product Profile - Masitinib
Table 82: Masitinib SWOT Analysis, 2017
Table 83: Product Profile - Lynparza
Table 84:Efficacy of Lynparza in mCRPC
Table 85: Lynparza SWOT Analysis, 2017
Table 86: Product Profile - Rubraca
Table 87: Rubraca SWOT Analysis, 2017
Table 88: Product Profile - Ipatasertib
Table 89:Efficacy of Ipatasertib in mCRPC
Table 90: Efficacy of Ipatasertib in mCRPC According to PTEN Status
Table 91: Ipatasertib SWOT Analysis, 2017
Table 92: Product Profile - Relugolix
Table 93:Efficacy of Relugolix in HNPC
Table 94: Relugolix SWOT Analysis, 2017
Table 95: Early-Stage Agents Targeting the P13K/AKT/mTOR Pathway
Table 96: Immune Checkpoint Inhibitors in Early-Stage Development for mCRPC
Table 97: PSMA-Targeted Therapeutics in Early-Stage Development for mCRPC
Table 98: Hormonal Therapies in Early-Stage Development for mCRPC
Table 99: Drugs in Development for PCa, 2017, Part 1
Table 100: Drugs in Development for PCa, 2017, Part 2
Table 101: Drugs in Development for PCa, 2017, Part 3
Table 102: Key Companies in the PCa Market in the 7MM, 2016-2026
Table 103: Astellas’ PCa Portfolio Assessment, 2017
Table 104: AstraZeneca’s PCa Portfolio Assessment, 2017
Table 105: Bayer’s PCa Portfolio Assessment, 2017
Table 106: Clovis Oncology’s PCa Portfolio Assessment, 2017
Table 107: J&J’s PCa Portfolio Assessment, 2017
Table 108: Pfizer’s PCa Portfolio Assessment, 2017
Table 109: Roche’s PCa Portfolio Assessment, 2017
Table 110: Sanofi’s PCa Portfolio Assessment, 2017
Table 111: Prostate Cancer Market - Global Drivers and Barriers, 2016-2026
Table 112: Key Events Impacting Sales for Prostate Cancer in the US, 2016-2026
Table 113: Prostate Cancer Market - Global Drivers and Barriers in the US, 2016-2026
Table 114: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2016-2026
Table 115: Prostate Cancer Market - Global Drivers and Barriers in the 5EU, 2016-2026
Table 116: Prostate Cancer Market in the 5EU - Country-Specific Barriers in the 5EU, 2016-2026
Table 117: Key Events Impacting Sales for Prostate Cancer in Japan, 2016-2026
Table 118: Prostate Cancer Market - Global Drivers and Barriers in Japan, 2016-2026
Table 119: Key Historical and Projected Launch Dates for Prostate Cancer
Table 120: Key Historical and Projected Patent Expiry Dates for Prostate Cancer
Table 121: Average Body Weight Across the 7MM
Table 122: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Prostate Cancer in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Prostate Cancer During the Forecast Period, 2016-2026
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Prostate Cancer, 2016-2026
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Men, Ages ≥35 Years, 2006-2026
Figure 5: Sources Used and Not Used for Calculations of Incident Cases
Figure 6: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases
Figure 7: Sources Used and Not Used for Calculations of Diagnosed Incident Cases by Stage at Diagnosis and Metastases
Figure 8: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases of CRPC
Figure 9: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases with HRD Mutations
Figure 10: 7MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016
Figure 11: 7MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Men, Ages ≥35 Years, 2016
Figure 12: 7MM, Diagnosed Incident Cases of Prostate Cancer by Risk of Biochemical Recurrence, Men, Ages ≥35 Years, 2016
Figure 13: 7MM, 10-Year Prevalent Cases of CRPC, Men, Ages ≥35 Years, 2016
Figure 14: 7MM, 10-Year Prevalent Cases of Prostate Cancer by Metastases, Men, Ages ≥35 Years, 2016
Figure 15: 7MM, 10-Year Prevalent Cases of Prostate Cancer with HRD Mutations, Men, Ages ≥35 Years, 2016
Figure 16: Treatment Algorithm for Localized Prostate Cancer
Figure 17: Treatment Algorithm for Progressive and Advanced Prostate Cancer
Figure 18: Zytiga’s Clinical Development in PCa
Figure 19: Xtandi’s Clinical Development in PCa
Figure 20: Xofigo’s Clinical Development in PCa
Figure 21: Provenge’s Clinical Development in PCa
Figure 22: Firmagon’s Clinical Development in PCa
Figure 23: Overview of the Unmet Need and Opportunity in Prostate Cancer, 2017
Figure 24: Overview of the Development Pipeline in PCa
Figure 25: Pivotal Phase II/III Trials for the Promising Pipeline Agents, Part 1
Figure 26: Pivotal Phase II/III Trials for the Promising Pipeline Agents, Part 2
Figure 27: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of PCa During the Forecast Period
Figure 28: ProstAtak Clinical Development in PCa
Figure 29: Clinical and Commercial Positioning of ProstAtak
Figure 30: Stapuldencel-t Clinical Development in PCa
Figure 31: Clinical and Commercial Positioning of Stapuldencel-t
Figure 32: ITK-1 Clinical Development in PCa
Figure 33: Clinical and Commercial Positioning of ITK-1
Figure 34: Tecentriq Clinical Development in PCa
Figure 35: Clinical and Commercial Positioning of Tecentriq
Figure 36: Apalutamide Clinical Development in PCa
Figure 37: Clinical and Commercial Positioning of Apalutamide
Figure 38: Darolutamide Clinical Development in PCa
Figure 39: Clinical and Commercial Positioning of Darolutamide
Figure 40: Masitinib Clinical Development in PCa
Figure 41: Clinical and Commercial Positioning of Masitinib
Figure 42: Lynparza Clinical Development in PCa
Figure 43: Clinical and Commercial Positioning of Lynparza
Figure 44: Rubraca Clinical Development in PCa
Figure 45: Clinical and Commercial Positioning of Rubraca
Figure 46: Ipatasertib Clinical Development in PCa
Figure 47: Clinical and Commercial Positioning of Ipatasertib
Figure 48: Relugolix Clinical Development in PCa
Figure 49: Clinical and Commercial Positioning of Relugolix
Figure 50: Global Sales of Branded Products for PCa by Company in 2016-2026
Figure 51: Analysis of the Company Portfolio Gap in PCa During the Forecast Period
Figure 52: Global (7MM) Sales Forecast by Country for Prostate Cancer in 2016 and 2026
Figure 53: Global (7MM) Sales Forecast by Drug Class for Prostate Cancer in 2016 and 2026
Figure 54: Sales Forecast by Class for Prostate Cancer in the US in 2016 and 2026
Figure 55: Sales Forecast by Class for Prostate Cancer in the 5EU in 2016 and 2026
Figure 56: Sales Forecast by Class for Prostate Cancer in Japan in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report